Digital process development for cell and gene therapy

Ori Biotech said its manufacturing platform combined with Benchling software improves digital process development for cell and gene therapy by reducing planning time between process runs, data entry errors and experimental workload. The London and New Jersey based company said the integration addresses challenges in process execution and optimization that rely on manual documentation and spreadsheets. Ori Biotech said its approach uses automation and a digitally native system to standardize data capture and enable real-time process visibility. The company said researchers can now shorten planning intervals, minimize data input inaccuracies and reduce experimental effort. Ori Biotech said the platform helps therapeutic developers accelerate market introduction of life saving products and ensure broad patient access. Benchling said its web based platform allows researchers to design and run experiments, analyze data and share results. The companies said the delivery of safe and effective cell and gene therapies hinges on efficient, scalable and adaptable process development.